R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 60.81
-1.49 (-2.39%)
At close: May 12, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 5.98 billion as of May 12, 2026. Its market cap has increased by 36.50% in one year.
Market Cap
5.98B
Enterprise Value
4.31B
Revenue
896.26M
Ranking
n/a
PE Ratio
44.45
Stock Price
60.81
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 5.98B, an increase of 10.73%. That is a compound annual growth rate of 2.74%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 11, 2026 | 5.98B | 5.55% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Anhui Huaheng Biotechnology | 6.84B |
| Innovita Biological Technology | 6.83B |
| Shouyao Holdings (Beijing) Co., LTD. | 6.19B |
| Novogene | 6.12B |
| Hangzhou Biotest Biotech | 6.08B |
| PharmaResources (Shanghai) | 5.86B |
| Lifecome Biochemistry | 5.86B |
| Shenzhen Weiguang Biological Products | 5.85B |